![TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products]()
by Admin | Jan 22, 2019 | News & Opinions
Glasgow, UK, 22 January 2019: TC BioPharm (TCB), a developer of CAR-T immuno-oncology products, including Gamma Delta T (GDT) cell therapies, today announced it has completed formulation of its first allogeneic GDT cell banks. The T cell banks provide TCB with core...
![TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products]()
by Admin | Jan 20, 2019 | News & Opinions
(MENAFN – GetNews) Phacilitate Leaders World, January 22-25, 2019, Miami, Florida Miami, FL – December 27, 2018 – Phacilitate:TALKS , sponsored by Anemocyte, is a brand new stage at this year’s Phacilitate Leaders World , a revolutionary...
![TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products]()
by Admin | Jan 20, 2019 | News & Opinions
CALGARY, Alberta, Jan. 17, 2019 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following corporate update on accomplishments and milestones that it has achieved in 2018. The past...
![TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products]()
by Admin | Jan 20, 2019 | News & Opinions
Groundbreaking stem cell therapy which allowed Jack Nicklaus to play golf again after years of back pain could help Andy Murray, scientists believe. Last year, Nicklaus 78, revealed that he had taken part in an experimental procedure which removed stem cells from his...
![TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products]()
by Admin | Jan 18, 2019 | News & Opinions
MIAMI, Jan. 18, 2019 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops cellular therapies for aging-related diseases, will play a prominent role when leading experts gather in Miami for the 2019 World Stem Cell Summit, Jan. 22-25 at the...
![TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products]()
by admin | Jan 18, 2019 | News & Opinions
EXTON, Pa., Jan. 16, 2019 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and...
